北京市30所医院肺恶性肿瘤患者的中药参与度分析

Analysis of participation degree of traditional Chinese medicine in lung malignant tumor cases from 30 hospitals in Beijing

目的探究影响患者中药参与的主要因素,为中药参与肺恶性肿瘤治疗提供参考。方法综合考虑社会人口学因素,选取北京市30所医院2016年1月—12月肺恶性肿瘤住院患者的信息,从中提取基本情况、住院治疗情况和中药参与情况等数据信息,对中药参与度的影响因素进行统计分析。结果共收集12163例肺恶性肿瘤住院患者的信息,有效例数为12099例。其中,男性患者比例高于女性,年龄在>60~80岁的患者比重最大,支付方式以城镇职工基本医疗保险为主,三级医院患者比例远高于二级医院,平均住院天数为(11.62±9.39)d。肺恶性肿瘤患者的中药总体参与度为69.30%,单因素分析结果显示,中药参与度在不同性别、年龄、支付方式、医院级别和住院天数比较,差异有统计学意义(P<0.05)。logistic回归结果显示,支付方式(OR=1.864)、医院级别(OR=1.435)和住院天数(OR=1.047)是肺部恶性肿瘤患者中药参与度的主要影响因素(P<0.05)。结论中药在肺恶性肿瘤治疗中的参与度可通过合理引导就医流向、探索中医特色诊疗方法、完善中医药服务价格体系等手段进一步提升,在发挥中医药优势作用的同时降低肺部恶性肿瘤的费用负担。

Objective To explore the main factors that affect patients’participation in traditional Chinese medicine,and to provide references for traditional Chinese medicine to participate in the treatment of lung malignant tumors.Methods Taking socio-demographic factors into consideration,a total of 30 hospitals in Beijing from January to December,2016 were selected.The information of patients with lung malignant tumors was extracted from them,and the basic information,hospitalization status,and participation in traditional Chinese medicine were extracted.The factors affecting participation were analyzed statistically.Results A total of 12163 hospitalized patients with lung malignant tumors were collected,and the effective number of cases was 12099 cases.Among them,the proportion of male patients was higher than that of females,and the proportion of patients aged>60-80 years was the largest.The payment method was mainly urban employee basic medical insurance,and the proportion of patients in tertiary hospitals was much higher.In a secondary hospital,the average hospital stay was(11.62±9.39)days.The overall participation rate of traditional Chinese medicine in patients with lung malignant tumors was 69.30%.The single-factor analysis showed that the participation rate of traditional Chinese medicine was statistically significant in different genders,ages,payment methods,hospital levels and length of stay in hospital(P<0.05).The logistic regression results showed that payment method(OR=1.864),hospital level(OR=1.435)and hospital stay(OR=1.047)were the main factors affecting the participation of traditional Chinese medicine in patients with lung malignant tumors(P<0.05).Conclusion The participation of traditional Chinese medicine in the treatment of lung malignant tumors can be further enhanced by rationally guiding the flow of medical treatment, exploring the characteristics of traditional Chinese medicine diagnosis and treatment methods, and improving the price system of traditional Chinese medicine services, which can reduce the cost burden of lung cancer while exerting the advantages of traditional Chinese medicine.